Enhanced sensitization to Taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5703-5710

  Lee, Sangkyou ^a   Yang, Wentao ^a   Lan, Keng Hsueh ^a   Sellappan, Shankar ^a   Klos, Kristine ^a   Hortobagyi, Gabriel ^a   Hung, Mien Chie ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN KINASE; PROTEIN P21; TRASTUZUMAB; TYROSINE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOWN-REGULATION; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; MICE, INBRED ICR; MICE, SCID; PACLITAXEL; PHOSPHORYLATION; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037108866     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., and Toyoshima, K. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor. Nature (Lond.), 319: 230-234, 1986.
2. Bargmann, C. I., Hung, M-C., and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond.), 319: 226-230, 1986.
3. Yu, D., and Hung, M-C. Role of erbB2 in breast cancer chemosensitivity. BioEssays, 22: 673-680, 2000.
4. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich. A., and McGuire, W. L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC). 235: 177-182, 1987.
5. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and McGuire, W. L. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712. 1989.
6. Yu, D., and Hung, M-C. HER-2/neu gene in human cancers. In: E. Freireich and S. A. Stass (eds.), Molecular Basis of Oncology, Vol. 5, pp. 131-162. Cambridge: Blackwell Scientific Publications, Inc., 1995.
7. Tauchi, K., Hori. S., Itoh H., Osamura, R. Y., Tokuda, Y., and Tajima. T. Immunohistochemical studies on oncogene products (c-erbB-2, epidermal growth factor receptor, c-myc) and estrogen receptor in benign and malignant breast lesions: With special reference to their prognostic significance in carcinoma. Virchows Arch. A Pathol. Anat. Histopathol., 416: 65-73, 1989.
8. Lacroix, H., Iglehart, J. D., Skinner, M. A., and Kraus, M. H. Overexpression of erbB-2 or EGF-receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastasis. Oncogene. 4: 145-151, 1989.
9. van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., and Nusse, R. Neu-protein overexpression in breast cancer: Association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med., 319: 1239-1245, 1988.
10. Tan, M., Yao, J., and Yu, D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastatic potential in human breast cancer cells without increasing their transformation abilities. Cancer Res., 57: 1199-1205, 1997.
11. mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene, 16: 2087-2094, 1998b.
12. Cdc2 kinase. Molecular Cell, 2: 581-591, 1998.
13. Baselga, J., Norton, L., Albanell, J., Kim. Y-M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
14. Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., and Slamon, D.J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
15. Dickman, S. Antibodies stage a comeback in cancer treatment. Science (Wash. DC). 280: 1196-1197, 1998.
16. Shepard, H. M., Lewis. G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I. Kotts, C. E. Palladino, M. A., Jr., Ullrich, A., and Slamon, D. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J. Clin. Immunol., 11: 117-127, 1991.
17. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, 1. C., and Norton, L. Phase 11 study of weekly intravenous recombinant humanized anti-p185her2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
18. Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A. and Slamon, D. J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 17: 2235-2249, 1998.
19. Holmes. F. A., Walters, R. S., Theriault, R. L., Forman, A. D., Newton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K., and Hortobagyi, G. N. Phase 11 trial of Taxol an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797-1805, 1991.
20. Chevalier. B., Fumoleau, P., Kerbrat. P., Dieras, V., Roche. H., Krakowski, I., Azli, N., Bayssas, M., Lentz. M. A., and Van Glabbeke, M. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A Phase 2 trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 13: 314-322. 1995.
21. Horwitz, S. B. Mechanism of action of Taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
22. Wahl. A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., and Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
23. Lee, L. F., Li, G.,_ Templeton, D. J., and Ting, J. P. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J. Biol. Chem., 273: 28253-28260, 1998.
24. Wang, T. H., Popp, D. M., Wang, H, S., Saitoh, M., Mural, J. G., Henley, D. C., Ichijo, H., and Wimalasena, J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem., 274: 8208-8216, 1999.
25. Yamamoto, K., lchijo, H., and Korsmeyer, S. J. BCL-2 phosphorylated and inactivated by an ASKI/Jun N-terminal protein kinase pathway normally activated at G(2)/M Mol. Cell Biol., 19: 8469-8478, 1999.
26. Huang, Y., Johnson, K. R., Norris, J. S., and Fan, W. Nuclear factor-κB/lκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res., 60: 4426-4432, 2000.
27. Yang, C. P., and Horwitz. S. B. Taxol mediates serine phosphorylation of the 66-kDa Shc isoform. Cancer Res., 60: 5171-5178, 2000.
28. Bacus, S. S., Gudkov, A. V., Lowe, M., Lyass, L., Yung. Y., Komarov. A. P., Keyomarsi, K., Yarden. Y., and Seger, R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene., 20: 147-155. 2001.
29. Tan, M., Jing, T., Lan. K-H., Neal. C. L., Li, P., Lee. S., Fang. D., Nagata, Y., Liu, J., Arlinghaus, R., Hung, M. C., and Yu, D. Phosphorylation on tyrosine-15 of p34Cdc2 by ErbB2 inhibits p34Cdc2 activation and is involved in resistance to Taxol-induced apoptosis. Mol. Cell. 9: 993-1004, 2002.
30. Coleman, T. R., and Dunphy, W. G. Cdc2 regulatory factors. Curr, Opin. Cell Biol., 6: 877-882, 1994.
31. Darzynkiewicz, Z., Bruno, S., Del Bino. G., Gorczyca, W., Hotz, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry. Cytometry. 13: 795-808, 1991
32. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology, 61 (Suppl. 2): 1-13, 2001.
33. Madhani H. D. Accounting for specificity in receptor tyrosine kinase signaling. Cell, 106: 9-11, 2001.
34. Stebbing, J., Copson, E., and O'Reilly. S, Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat. Rev., 26: 287-290, 2000.
35. Kip1-Cdk2 complex formation: Receptor overexpression does not determine growth dependency. Mol. Cell Biol., 20: 3210-3223, 2000.
36. Slamon, D. J., Leyland-Jones. B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann. W., Wolter. J., Pegram. M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
37. , Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert. N. J., Scholl. S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., and Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639-2648, 1999.